Garnet Pharmaceutical

Garnet BioTherapeutics was a clinical-stage regenerative medicine company focused on developing cell-based therapies to improve tissue repair and reduce inflammation. The company's core technology utilized allogeneic bone marrow-derived cells for applications in dermatology and orthopedics, specifically targeting wound healing and the reduction of post-surgical scarring. Its lead product candidate, GBT009, reached Phase 2 clinical trials and demonstrated potential for improving cosmetic outcomes following surgery. Founded in 2003 and based in Malvern, Pennsylvania, Garnet was acquired by Fibrocell Science in 2011 to integrate its allogeneic cell therapy technology into Fibrocell's aesthetic and medical pipeline. The company's research was originally based on technology licensed from the University of Pennsylvania.